The aim of the present study was to compare the expression of transforming growth factor (TGF) beta 1 in ameloblastomas (AMs) with different risk of recurrence by immunohistochemistry. A total of 29 cases of AMs were evaluated. The tumors were divided into 2 groups: group A (10 cases) composed of unicystic and peripheral AMs, associated with a low risk of recurrence, and group B (19 cases) composed of solid AMs, associated with a high risk of recurrence. Statistical evaluation showed significant differences between groups A and B lesions, with higher values of positivity for TGF-beta 1 in stromal cells in group B tumors (P = 0.0308). No statistically significant differences of immunoreactivity were found in vessels and odontogenic epithelium between the 2 groups. The increased TGF-beta 1 expression in tumors with a high risk of recurrence could be explained with the fact that although TGF-beta acts as a potent tumor suppressor in the early stages of tumor progression, later it seems to enhance the invasive phenotype of the tumor.
Expression of transforming growth factor beta1 in ameloblastomas.
IEZZI, GIOVANNA;PIATTELLI, Adriano;PERROTTI, Vittoria;
2008-01-01
Abstract
The aim of the present study was to compare the expression of transforming growth factor (TGF) beta 1 in ameloblastomas (AMs) with different risk of recurrence by immunohistochemistry. A total of 29 cases of AMs were evaluated. The tumors were divided into 2 groups: group A (10 cases) composed of unicystic and peripheral AMs, associated with a low risk of recurrence, and group B (19 cases) composed of solid AMs, associated with a high risk of recurrence. Statistical evaluation showed significant differences between groups A and B lesions, with higher values of positivity for TGF-beta 1 in stromal cells in group B tumors (P = 0.0308). No statistically significant differences of immunoreactivity were found in vessels and odontogenic epithelium between the 2 groups. The increased TGF-beta 1 expression in tumors with a high risk of recurrence could be explained with the fact that although TGF-beta acts as a potent tumor suppressor in the early stages of tumor progression, later it seems to enhance the invasive phenotype of the tumor.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
